Seattle Genetics, Inc. (SGEN)

Check out top investors' recommendation for SGEN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company’s ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Cory Kasimov JPMorgan Buy   Oct 21, '19       Oct 21, '20  N/A 
Geoff Meacham JPMorgan Buy   Feb 08, '19     85.00  Feb 08, '20  N/A 
Chad Messer Needham & Company Buy   Feb 08, '19     81.00  Feb 08, '20  N/A 
Andrew Fein Chardan Capital Markets Buy   Feb 08, '19     98.00  Feb 08, '20  N/A 
Geoff Meacham JPMorgan Buy   Oct 03, '18     95.00  Oct 03, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Oct 02, '18     98.00  Oct 02, '19  N/A 
Cory Kasimov JPMorgan Buy   Sep 26, '18     85.00  Sep 26, '19  N/A 
Chad Messer Needham & Company Buy   Jul 27, '18     79.00  Jul 27, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Jun 05, '18     77.00  Jun 05, '19  N/A 
Geoff Meacham JPMorgan Buy   Mar 20, '18     74.00  Mar 20, '19  N/A 
Cory Kasimov JPMorgan Buy   Feb 14, '18     66.00  Feb 14, '19  N/A 
Chad Messer Needham & Company Buy   Feb 07, '18     74.00  Feb 07, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Feb 01, '18     75.00  Feb 01, '19  N/A 
Andrew Fein Chardan Capital Markets Buy   Oct 27, '17     75.00  Oct 27, '18  N/A 
Adnan Butt RBC Capital Markets Buy   Oct 23, '17     72.00  Oct 23, '18  N/A 
Geoff Meacham JPMorgan Buy   Oct 20, '17     70.00  Oct 20, '18  N/A 
Alan Carr Needham & Company Buy   Sep 15, '17     72.00  Sep 15, '18  N/A 
Eun Yang Jefferies & Co. Buy   Sep 12, '17     53.00  Sep 12, '18  N/A 
Michael Schmidt Leerink Swann Llc Buy   Jun 20, '17     66.00  Jun 20, '18  N/A 
Andrew Fein Chardan Capital Markets Buy   Jun 19, '17     75.00  Jun 19, '18  N/A 
< previous123